STOCK TITAN

Cognition Therapeutics Inc - CGTX STOCK NEWS

Welcome to our dedicated news page for Cognition Therapeutics (Ticker: CGTX), a resource for investors and traders seeking the latest updates and insights on Cognition Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cognition Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cognition Therapeutics's position in the market.

Rhea-AI Summary
Cognition Therapeutics reports positive topline results from CT1812 Phase 2 SEQUEL study in Alzheimer's disease and provides recent business updates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.86%
Tags
-
Rhea-AI Summary
Cognition Therapeutics, Inc. (Nasdaq: CGTX) to Release Q2 Financial Results and Host Conference Call on August 8, 2023. The clinical-stage neuroscience company will review financial results and provide a business update. Investors can access the live webcast on the company website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.98%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.01%
Tags
none
-
Rhea-AI Summary
Cognition Therapeutics announces positive results from Phase 2 study of CT1812 in Alzheimer's disease
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.8%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.8%
Tags
conferences clinical trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.33%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.05%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.85%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.94%
Tags
none
Cognition Therapeutics Inc

Nasdaq:CGTX

CGTX Rankings

CGTX Stock Data

76.44M
32.88M
6.5%
34.19%
0.39%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States
Purchase

About CGTX

cognition therapeutics inc. is a drug discovery and development company located in pittsburgh, pennsylvania. founded in 2007, the company uses proprietary biology and chemistry platforms to discover novel drug targets and disease modifying therapies for disorders of the central nervous system.